High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Pietro Lampertico, Roberta D’Ambrosio et al.|Journal of Hepatology|2020Cited by 392
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Francesco Paolo Russo, Fabio Farinati et al.|The Lancet Oncology|2023Cited by 184
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Pietro Lampertico, Roberta D’Ambrosio et al.|Clinical Gastroenterology and Hepatology|2018Cited by 114
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVRRoberta D’Ambrosio, Pietro Lampertico, Elisabetta Degasperi et al.|Journal of Hepatology|2021Cited by 75
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAsElisabetta Degasperi, Pietro Lampertico, E. Galmozzi et al.|Hepatology|2020Cited by 67